The objective of this project is to identify the signal transduction pathways which control growth versus apoptosis of lung cancer cells. This information will be used to develop new therapeutic strategies for the prevention and treatment of lung cancer. A focus is given to lung cancers having neuroendocrine properties characteristic of small cell lung carcinoma. Lung cancers having neuroendocrine properties generally express neuropeptides such as gastrin releasing peptide (GRP) and the receptors for neuropeptides. The neuropeptide receptors are seven transmembrane receptors coupled to heterotrimic G proteins generally of the Gq,11 and G12, 13 family. Neuropeptide autocrine and paracrine stimulation of lung cancers having neuroendocrine features stimulate cell growth and proliferation. Studies during the past three years have demonstrated that disruption of neuropeptide autocrine/paracrine signal transduction induces apoptosis, a programmed cell death response of lung cancer cells having neuroendocrine features. Both pharmacologic and genetic disruption of neuropeptide autocrine/paracrine signaling induces apoptosis o small cell lung carcinoma cells. Dissection of signal transduction pathways in small cell lung carcinoma and other cell types indicates that a sequential protein kinase pathway involving the serine/threonine protein kinase referred to as MEK kinase (MEK) regulates apoptosis. This discovery is being used to develop gene therapy strategies for selective expression of activated MEK kinase genes and induciton of apoptosis of lung cancer cells having neuroendocrine properties. In addition, pharmacological strategies are being developed using antagonist peptides that allosterically alter the signaling of neuropeptide receptors to convert a growth stimulatory response to an apoptotic response. The antagonist peptides induce apoptosis by inhibiting specific growth stimulatory responses and activating specific MEK kinase pathways. These studies will be performed with lung cancer cells in culture and also in nude mouse tumor models. In collaboration with other project investigators of the SPORE signal transduction pathways regulating apoptosis of primary human dysplastic lung cells will be defined. Genetic and pharmacological induction of apoptosis will be characterized for lung cell dysplasias. Cumulatively, the in vitro studies to define mechanism and in vivo studies in animals will allow us to design protocols to induce apoptosis of lung cancer cells. Ultimately, these studies will be developed to a point that they can enter human clinical trials

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058187-08S4
Application #
6657495
Study Section
Project Start
2000-05-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
$61,783
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105

Showing the most recent 10 out of 435 publications